Effect of Prior Bilateral Oophorectomy on the Presentation of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
- PMID: 20223030
- PMCID: PMC2837298
- DOI: 10.1186/1897-4287-3-2-53
Effect of Prior Bilateral Oophorectomy on the Presentation of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
Abstract
Purpose: To compare the presentation of invasive breast cancer in BRCA1 and BRCA2 mutation carriers with and without prior bilateral oophorectomy.
Patients and methods: Women with a BRCA1 or BRCA2 mutation with the diagnosis of invasive breast cancer were identified from ten cancer genetics clinics. The medical history, medical treatment records and pathology reports for the breast cancers were reviewed. Information was abstracted from medical charts, including history (and date) of oophorectomy, date of breast cancer diagnosis, stage of disease, and pathologic characteristics of the breast cancer. Women with prior bilateral oophorectomy were matched by age, year of diagnosis, and mutation with one or more women who had two intact ovaries at the time of breast cancer diagnosis. Characteristics of the breast tumours were compared between the two groups.
Results: Women with prior bilateral oophorectomy presented with smaller tumours on average compared to women without prior oophorectomy (mean size 1.50 cm vs. 1.95 cm; p = 0.01). Additionally, although not statistically significant, women with intact ovaries were more likely to have high-grade tumour (70% vs. 54%: p = 0.10) and to have positive lymph nodes (34% vs. 18%; p = 0.11) compared to women with prior bilateral oophorectomy.
Conclusions: Bilateral oophorectomy prior to breast cancer appears to favourably influence the biological presentation of breast cancer in BRCA1 and BRCA2 mutation carriers.
Similar articles
-
Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.JAMA Oncol. 2015 Jun;1(3):306-13. doi: 10.1001/jamaoncol.2015.0658. JAMA Oncol. 2015. PMID: 26181175
-
Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations.Am J Obstet Gynecol. 2021 Nov;225(5):508.e1-508.e10. doi: 10.1016/j.ajog.2021.06.070. Epub 2021 Jun 23. Am J Obstet Gynecol. 2021. PMID: 34171390
-
Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.Gynecol Oncol. 2005 May;97(2):457-67. doi: 10.1016/j.ygyno.2005.01.039. Gynecol Oncol. 2005. PMID: 15863145
-
Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation.Climacteric. 2016 Oct;19(5):419-22. doi: 10.1080/13697137.2016.1209396. Epub 2016 Jul 16. Climacteric. 2016. PMID: 27426853 Review.
-
The Role of Hormonal Replacement Therapy in BRCA Mutated Patients: Lights and Shadows.Int J Mol Sci. 2023 Jan 1;24(1):764. doi: 10.3390/ijms24010764. Int J Mol Sci. 2023. PMID: 36614207 Free PMC article. Review.
Cited by
-
Breast cancer risk in BRCA mutation carriers after diagnosis of epithelial ovarian cancer is lower than in carriers without ovarian cancer.Gynecol Oncol Rep. 2021 Dec 4;39:100899. doi: 10.1016/j.gore.2021.100899. eCollection 2022 Feb. Gynecol Oncol Rep. 2021. PMID: 34917730 Free PMC article.
References
-
- Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117–1130. doi: 10.1086/375033. - DOI - PMC - PubMed
-
- Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL. Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346(21):1616–1622. doi: 10.1056/NEJMoa012158. - DOI - PubMed
-
- Zavagno G, Meggiolaro F, Pluchinotta A, Bozza F, Favretti F, Marconato R, Geraci G, Nistri R, Fontana P, Sorrentino P, Lumachi F, Toniato A, Rossi CR, Lise M. Influence of age and menopausal status on pathologic and biologic features of breast cancer. Breast. 2000;9(6):320–328. doi: 10.1054/brst.1999.0147. - DOI - PubMed
-
- Metcalfe KA, Snyder C, Seidel J, Hanna D, Lynch H, Narod S. The use of tamoxifen and other preventive measures among health women who carry a BRCA1 or BRCA2 mutation. Fam Cancer. 2004. in press . - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous